Table 1. Long-term survival in NSCLC with PD-1/PD-L1 inhibitors.

Drugs	Clinical trials	2-year OS (%)	3-year OS (%)	5-year OS (%)
Pembrolizumab	Keynote 001 (treated native pts vs. previously treated pts)	44.5 vs. 31.3	26.4 vs. 19.0	Keynote 010 21.5
Nivolumab	CM017 (SQ) (Nivo vs. docetaxel)	23.0 vs. 8.0	16.0 vs. 6.0	CA209-003 SQ vs. non-SQ: 16.0 vs. 15.0
	CM057 (non-SQ) (Nivo vs. docetaxel)	29.0 vs. 16.0	18.0 vs. 9.0
Atezolizumab	OAK (Atezo vs. docetaxel)	31.0 vs. 21.0	–	–

NSCLC, non-small cell lung cancer; Pts, patients; CM, checkmate; SQ, squamous lung cancer; non-SQ, non-squamous lung cancer; Nivo, nivolumab; Atezo, atezolizumab; OS, overall survival.